Currently, several phase 3 global, randomized, open-label clinical studies, including BELLWAVE-011 (NCT06136559) evaluating newly diagnosed CLL and SLL patients, and BELLWAVE-008 (NCT05624554) focusing on previously untreated CLL and SLL patients without TP53 aberrations, are underway and hold promise [61]. Here, TP53 is linked to B-cell chronic lymphocytic leukemia.